A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke

Annals of Neurology

Volumn 72, Issue 5, 2012, Pages 716-729

  Del Río Espínola, Alberto ^a   Fernández Cadenas, Israel ^a   Giralt, Dolors ^a   Quiroga, Adoracion ^b   Gutiérrez Agullõ, Maria ^b   Quintana, Manuel ^b   Fernández Álvarez, Patricia ^b   Domingues Montanari, Sophie ^a   Mendiõroz, Maite ^a   Delgado, Pilar ^a   Turck, Natacha ^c   Ruíz, Agustin ^d   Ribõ, Marc ^b   Castellanos, Mar ^e   Obach, Victor ^f   Martínez, Sergi ^g   Freijo, Mari Mar ^h   Jiménez Conde, Jordi ⁱ   Cuadrado Godia, Elisa ⁱ   Roquer, Jaume ⁱ   Chacõn, Pilar ^b   Martí Fábregas, Joan ^g   Sánchez, Jean Charles ^c   Montaner, Joan ^a   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d Neocodex ^*  (Spain)

^e GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 12; C REACTIVE PROTEIN; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN A; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHELOMETRY; NEUROIMAGING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; WESTERN BLOTTING;

ALPHA-MACROGLOBULINS; CASE-CONTROL STUDIES; COHORT STUDIES; FACTOR XII; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MODELS, GENETIC; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SPAIN; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871944317     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23664     Document Type: Article

References (37)

1. Wahlgren N, Ahmed N, Dávalos A, et al. SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008; 372: 1303-1309.
2. National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
3. Thanvi BR, Treadwell S, Robinson T,. Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors. Postgrad Med J 2008; 84: 361-367.
4. Castellanos M, Sobrino T, Millán M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke 2007; 38: 1855-1859. (Pubitemid 46847259)
5. Mendioroz M, Fernández-Cadenas I, Alvarez-Sabín J, et al. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients. Cerebrovasc Dis 2009; 28: 143-150.
6. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491-2495. (Pubitemid 47329627)
7. Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tPA treatment in stroke. Stroke 2010; 41: 1528-1535.
8. Lou M, Safdar A, Mehdiratta M, et al. The HAT score: A simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008; 71: 1417-1423.
9. Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA, et al. Proyecto Ictus Research Group. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006; 37: 2288-2293. (Pubitemid 44337171)
10. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
11. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685. (Pubitemid 34298612)
12. Hosmer DW, Lemeshow S,. Applied logistic regression. New York, NY: John Wiley & Sons, 1989: 89-91.
13. Hanley JA, McNeil BJ,. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843. (Pubitemid 13033817)
14. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172. (Pubitemid 351193639)
15. Janssens AC, Ioannidis JP, Bedrosian S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Hum Genet 2011; 19: 18.
16. Little J, Higgins JP, Ioannidis JP, et al. STREGA. STrengthening the REporting of Genetic Association Studies (STREGA): An extension of the STROBE statement. PLoS Med 2009; 6: e22.
17. Sánchez MC, Chiabrando GA, Guglielmone HA, et al. Interaction of human tissue plasminogen activator (t-PA) with pregnancy zone protein: A comparative study with t-PA-alpha2-macroglobulin interaction. J Biochem 1998; 124: 274-279. (Pubitemid 28419669)
18. Arbeláez LF, Bergmann U, Tuuttila A, et al. Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2- macroglobulin. Arch Biochem Biophys 1997; 347: 62-68. (Pubitemid 27484021)
19. Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-1126. (Pubitemid 351440679)
20. Cuadrado E, Ortega L, Hernández-Guillamon M, et al. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 2008; 84: 207-214. (Pubitemid 351960296)
21. Cucullo L, Marchi N, Marroni M, et al. Blood-brain barrier damage induces release of alpha2-macroglobulin. Mol Cell Proteomics 2003; 2: 234-241.
22. Poller W, Faber JP, Klobeck G, Olek K,. Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: The bait region and the thiolester site. Hum Genet 1992; 88: 313-319.
23. Pauer HU, Renné T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII gene-A model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-508. (Pubitemid 39248007)
24. Hovinga JK, Schaller J, Stricker H, et al. Coagulation factor XII Locarno: The functional defect is caused by the amino acid substitution Arg 353->Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173-1181. (Pubitemid 24245882)
25. Renné T, Nieswandt B, Gailani D,. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 2006; 36: 148-151.
26. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
27. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014. (Pubitemid 28185502)
28. Calafell F, Almasy L, Sabater-Lleal M, et al. Sequence variation and genetic evolution at the human F12 locus: mapping quantitative trait nucleotides that influence FXII plasma levels. Hum Mol Genet 2010; 19: 517-525.
29. Bach J, Endler G, Winkelmann BR, et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-296.
30. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104. (Pubitemid 44853481)
31. Latacha MP, Schaiff WT, Eisenberg PR, Abendschein DR,. Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis. J Thromb Haemost 2004; 2: 128-134. (Pubitemid 40185629)
32. Pönitz V, Pritchard D, Grundt H, Nilsen DW,. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J Thromb Thrombolysis 2006; 22: 199-203. (Pubitemid 44857781)
33. Molinaro G, Gervais N, Adam A,. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: An in vitro experimental approach. Stroke 2002; 33: 1712-1716. (Pubitemid 34619983)
34. Kamiya T, Katayama Y, Kashiwagi F, Terashi A,. The role of bradykinin in mediating ischemic brain edema in rats. Stroke 1993; 24: 571-576. (Pubitemid 23100745)
35. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011; 17: 206-210.
36. Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60: 1525-1527. (Pubitemid 36554818)
37. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002; 303: 232-237.